Cargando…

The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies

Hypercholesterolemia is a clinically relevant condition with an ascertained role in atherogenesis. In particular, its presence directly correlates to the risk of atherosclerotic cardiovascular disease (ASCVD). As known, cardiovascular diseases pose a significant economic burden worldwide; however, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrara, Pietro, Di Laura, Danilo, Cortesi, Paolo A., Mantovani, Lorenzo G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274865/ https://www.ncbi.nlm.nih.gov/pubmed/34252164 http://dx.doi.org/10.1371/journal.pone.0254631

Ejemplares similares

Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
por: Ferrara, Pietro, et al.
Publicado: (2021)

The Draupadi of dyslipidemia: Familial hypercholesterolemia
por: Kalra, Sanjay, et al.
Publicado: (2016)

Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters
por: Vosper, Helen
Publicado: (2011)

Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Viljoen, Adie, et al.
Publicado: (2010)

Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Hussein, Ayman A, et al.
Publicado: (2010)

Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
por: Parhofer, Klaus G
Publicado: (2009)

Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia
por: Sasaki, Jun
Publicado: (2010)

Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia
por: Fukami, Hirotaka, et al.
Publicado: (2021)

Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

Prevalence of dyslipidemia and hypercholesterolemia awareness: results from the Lookup 7+ online project
por: Martone, Anna Maria, et al.
Publicado: (2022)

Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial
por: Tan, Hong, et al.
Publicado: (2023)

Successful Genetic Screening and Creating Awareness of Familial Hypercholesterolemia and Other Heritable Dyslipidemias in the Netherlands
por: Zuurbier, Linda C., et al.
Publicado: (2021)

Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia
por: Surma, Stanisław, et al.
Publicado: (2023)

The red blood cell as a mediator of endothelial dysfunction in patients with familial hypercholesterolemia and dyslipidemia
por: Mahdi, Ali, et al.
Publicado: (2022)

Economic impact of delirium in Australia: a cost of illness study
por: Pezzullo, Lynne, et al.
Publicado: (2019)

Mapping of familial hypercholesterolemia and dyslipidemias basic management infrastructure in Pakistan: a cross-sectional study
por: Sadiq, Fouzia, et al.
Publicado: (2023)

The economic burden of stroke: a systematic review of cost of illness studies
por: Strilciuc, Stefan, et al.
Publicado: (2021)

Cost‐minimization analysis of a wearable cardioverter defibrillator in adult patients undergoing ICD explant procedures: Clinical and economic implications
por: Boriani, Giuseppe, et al.
Publicado: (2021)

Improving care through health economics analyses: cost of illness and headache
por: Mennini, Francesco Saverio, et al.
Publicado: (2008)

Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Economic Burden of Myocardial Infarction Combined With Dyslipidemia
por: Chen, Pingyu, et al.
Publicado: (2021)

Phytosterol supplementation in the treatment of dyslipidemia in children and adolescents: a systematic review
por: Mantovani, Luisa Montone, et al.
Publicado: (2020)

Economic burden of maternal morbidity – A systematic review of cost-of-illness studies
por: Moran, Patrick S., et al.
Publicado: (2020)

Global systematic review of cost of illness and economic evaluation studies associated with snakebite
por: Patikorn, Chanthawat, et al.
Publicado: (2020)

The economic costs of illness: A replication and update
por: Rice, Dorothy P., et al.
Publicado: (1985)

Economic Impact of Dengue Illness and the Cost-Effectiveness of Future Vaccination Programs in Singapore
por: Carrasco, Luis R., et al.
Publicado: (2011)

Severe Dyslipidemia Mimicking Familial Hypercholesterolemia Induced by High-Fat, Low-Carbohydrate Diets: A Critical Review
por: Houttu, Veera, et al.
Publicado: (2023)

The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2023)

Economic costs of obesity in Thailand: a retrospective cost-of-illness study
por: Pitayatienanan, Paiboon, et al.
Publicado: (2014)

Mixed dyslipidemias in primary care patients in France
por: Laforest, Laurent, et al.
Publicado: (2012)

A systematic literature review of economic evaluations and cost-of-illness studies of inherited cardiomyopathies
por: Wiethoff, Isabell, et al.
Publicado: (2023)

Cost of illness and economic burden of chronic lymphocytic leukemia
por: Blankart, Carl Rudolf, et al.
Publicado: (2013)

Synergistic Effects of Inflammation and Atherogenic Dyslipidemia on Subclinical Carotid Atherosclerosis Assessed by Ultrasound in Patients with Familial Hypercholesterolemia and Their Family Members
por: Lin, Po-Chih, et al.
Publicado: (2022)

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study
por: Restelli, Umberto, et al.
Publicado: (2017)

Socio-economic burden of cystic fibrosis in Europe: a systematic review of cost of illness evidence
por: D'Ambrosio, F, et al.
Publicado: (2023)

The economic burden of obesity in Italy: a cost-of-illness study
por: d’Errico, Margherita, et al.
Publicado: (2021)

Economic Impact of Dengue Illness in the Americas
por: Shepard, Donald S., et al.
Publicado: (2011)

The scope of costs in alcohol studies: Cost-of-illness studies differ from economic evaluations
por: van Gils, Paul F, et al.
Publicado: (2010)

Low-Cost High-Throughput Genotyping for Diagnosing Familial Hypercholesterolemia
por: Ibrahim, Shirin, et al.
Publicado: (2023)

Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment
por: Cortesi, Paolo Angelo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_s4m1r2k91rkp8hc8ii1b0u10uv